The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test, percent appropriately prescribed a medication for osteoporosis, and compliance (% of those prescribed osteoporosis medications that continue with them for at least 6 months) among at risk patients.

Condition	Intervention
Osteoporosis	Behavior: Disease Management Assessment

Further Study Details: 

Primary Outcomes: Bone mineral density (BMD) testing rates
Secondary Outcomes: Osteoporosis medication treatment rates and medication
Expected Total Enrollment:  9369

Ages Eligible for Study:  45 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Members of the Horizon Blue Cross who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

Exclusion Criteria:

• Individuals who are not members of Horizon Blue and who otherwise do not meet the inclusion criteria.

Study chairs or principal investigators

Medical Monitor,  Study Director,  Merck   

Study ID Numbers:  2005_049
Last Updated:  September 7, 2005
Record first received:  August 29, 2005
ClinicalTrials.gov Identifier:  NCT00139438
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13